Effects of 15-deoxy-Δ12,14-prostaglandin J2 on the dxpression of p53 in MCF-7 cells

Annals of the New York Academy of Sciences

Volumn 1171, Issue , 2009, Pages 202-209

  Kim, Do Hee ^a   Kim, Eun Hee ^a   Na, Hye Kyung ^a   Surh, Young Joon ^a  

^a Seoul National University   (South Korea)

Author keywords

15 deoxy 12,14 prostaglandin J2; Human breast cancer cells; MCF 7 cells; p53

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2 CYCLOPENTEN 1 ONE; CARBONYL DERIVATIVE; CYCLOPENTENONE DERIVATIVE; DNA; PROSTAGLANDIN A2; PROTEIN P53; UNCLASSIFIED DRUG;

BINDING AFFINITY; BREAST CANCER; CELL NUCLEUS; CELL STRAIN MCF 7; CONFERENCE PAPER; CYTOSOL; DNA BINDING; GENE ACTIVATION; HUMAN; HUMAN CELL; INHIBITION KINETICS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEOMICS; TUMOR SUPPRESSOR GENE;

EID: 69149110305     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04913.x     Document Type: Conference Paper

References (35)

1. 12,14-prostaglandin J(2): the endogenous electrophile that induces neuronal apoptosis. Proc. Natl. Acad. Sci. USA 99 : 7367 7372.
2. Smith, W.L. 1992. Prostanoid biosynthesis and mechanisms of action. Am. J. Physiol. 263 : F181 191.
3. Straus, D.S. C.K. Glass. 2001. Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med. Res. Rev. 21 : 185 210.
4. 2 induce apoptosis in L1210 cells. FEBS Lett. 321 : 209 214.
5. Zernecke, A. et al. 2003. Suppression of endothelial adhesion molecule up-regulation with cyclopentenone prostaglandins is dissociated from IkappaB-alpha kinase inhibition and cell death induction. FASEB J. 17 : 1099 1101.
6. Noyori, R. M. Suzuki. 1993. Organic synthesis of prostaglandins: advancing biology. Science 259 : 44 45.
7. 2 with intracellular glutathione and enhancement of its antiproliferative activity by glutathione depletion. Cancer Res. 50 : 1879 1885.
8. 1 and glutathione catalyzed by homogeneous glutathione S-transferases from human and rat liver. Biochim. Biophys. Acta 398 : 205 208.
9. 2: role of glutathione. FEBS Lett. 579 : 5803 5808.
10. 2-glutathione conjugate in L1210 mouse leukemia cells. Biochem. Pharmacol. 43 : 1053 1060.
11. 2 inhibition of NF-kappaB-DNA binding through covalent modification of the p50 subunit. J. Biol. Chem. 276 : 35530 35536.
12. 2 binds to and activates H-Ras. Proc. Natl. Acad. Sci. USA 100 : 4772 4777.
13. 2. J. Biol. Chem. 278 : 51251 51260.
14. Rossi, A. et al. 2000. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 403 : 103 108.
15. Shibata, T. et al. 2003. Thioredoxin as a molecular target of cyclopentenone prostaglandins. J. Biol. Chem. 278 : 26046 26054.
16. 2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc. Natl. Acad. Sci. USA 97 : 4844 4849.
17. Levonen, A.L. et al. 2004. Cellular mechanisms of redox cell signalling: role of cysteine modification in controlling antioxidant defences in response to electrophilic lipid oxidation products. Biochem. J. 378 : 373 382.
18. Delphin, C. et al. 1994. Characterization of baculovirus recombinant wild-type p53. Dimerization of p53 is required for high-affinity DNA binding and cysteine oxidation inhibits p53 DNA binding. Eur. J. Biochem. 223 : 683 692.
19. Rainwater, R. et al. 1995. Role of cysteine residues in regulation of p53 function. Mol. Cell Biol. 15 : 3892 3903.
20. Hainaut, P. J. Milner. 1993. Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. Cancer Res. 53 : 4469 4473.
21. Buzek, J. et al. 2002. Redox state of tumor suppressor p53 regulates its sequence-specific DNA binding in DNA-damaged cells by cysteine 277. Nucleic Acids Res. 30 : 2340 2348.
22. Chene, P. 1999. Mutations at position 277 modify the DNA-binding specificity of human p53 in vitro. Biochem. Biophys. Res. Commun. 263 : 1 5.
23. Brown, J.M. B.G. Wouters. 1999. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res. 59 : 1391 1399.
24. Lin, D.L. C. Chang. 1996. p53 is a mediator for radiation-repressed human TR2 orphan receptor expression in MCF-7 cells, a new pathway from tumor suppressor to member of the steroid receptor superfamily. J. Biol. Chem. 271 : 14649 14652.
25. Lane, D.P. 1992. Cancer. p53, guardian of the genome. Nature 358 : 15 16.
26. Levine, A.J., J. Momand C.A. Finlay. 1991. The p53 tumour suppressor gene. Nature 351 : 453 456.
27. Vogelstein, B. K.W. Kinzler. 1992. p53 function and dysfunction. Cell 70 : 523 526.
28. Moll, U.M. et al. 1995. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc. Natl. Acad. Sci. USA 92 : 4407 4411.
29. Moll, U.M., G. Riou A.J. Levine. 1992. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc. Natl. Acad. Sci. USA 89 : 7262 7266.
30. Na, H.K. Y.J. Surh. 2003. Peroxisome proliferator-activated receptor γ (PPARgamma) ligands as bifunctional regulators of cell proliferation. Biochem. Pharmacol. 66 : 1381 1391.
31. Kim, E.H. et al. 2004. Effects of cyclopentenone prostaglandins on the expression of heme oxygenase-1 in MCF-7 cells. Ann. N. Y. Acad. Sci. 1030 : 493 500.
32. Moos, P.J., K. Edes F.A. Fitzpatrick. 2000. Inactivation of wild-type p53 tumor suppressor by electrophilic prostaglandins. Proc. Natl. Acad. Sci. USA 97 : 9215 9220.
33. Mullally, J.E. et al. 2001. Cyclopentenone prostaglandins of the J series inhibit the ubiquitin isopeptidase activity of the proteasome pathway. J. Biol. Chem. 276 : 30366 30373.
34. 2 on proteasome. Biochemistry 42 : 13960 13968.
35. 2 by nuclear factor-kappa B and other cellular proteins. Bioorg. Med. Chem. Lett. 15 : 4057 4063.